Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: Relevance to glycemic control

Life Sciences

Volumn 118, Issue 2, 2014, Pages 268-273

  Abdelsaid, Mohammed ^a,c   Kaczmarek, Jessica ^c   Coucha, Maha ^c   Ergul, Adviye ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Bosentan; Diabetes; Endothelin; Metformin; Neovascularization; Vascular remodeling

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR; METFORMIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; SULFONAMIDE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOGRAPHY; ARTERY DIAMETER; ARTICLE; BRAIN CORTEX; CEREBROVASCULAR DISEASE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; GLYCEMIC CONTROL; MALE; METABOLIC PARAMETERS; MIDDLE CEREBRAL ARTERY; NEOVASCULARIZATION (PATHOLOGY); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; SURFACE AREA; THREE DIMENSIONAL IMAGING; VASCULAR REMODELING; ANIMAL; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; HYPERGLYCEMIA; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOPHYSIOLOGY;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIN RECEPTOR ANTAGONISTS; HYPERGLYCEMIA; MIDDLE CEREBRAL ARTERY; NEOVASCULARIZATION, PATHOLOGIC; RATS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; SULFONAMIDES; VASCULAR REMODELING;

EID: 84964698732     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2014.01.008     Document Type: Article

References (20)

1. Bailey, C.J., Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 22 (2008), 215–224.
2. Ergul, A., Li, W., Elgebaly, M.M., Bruno, A., Fagan, S.C., Hyperglycemia, diabetes and stroke: focus on the cerebrovasculature. Vascul Pharmacol 51 (2009), 44–49.
3. Faraci, F.M., Heistad, D.D., Regulation of large cerebral arteries and cerebral microvascular pressure. Circ Res 66 (1990), 8–17.
4. Garrafa, E., Caprara, V., Di Castro, V., Rosano, L., Bagnato, A., Spinella, F., Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells. Life Sci 91 (2012), 638–643.
5. Giacco, F., Brownlee, M., Oxidative stress and diabetic complications. Circ Res 107 (2010), 1058–1070.
6. Harris, A.K., Hutchinson, J.R., Sachidanandam, K., Johnson, M.H., Dorrance, A.M., Stepp, D.W., et al. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1. Diabetes 54 (2005), 2638–2644.
7. Kelly-Cobbs, A., Elgebaly, M.M., Li, W., Ergul, A., Pressure-independent cerebrovascular remodelling and changes in myogenic reactivity in diabetic Goto-Kakizaki rat in response to glycaemic control. Acta Physiol (Oxf) 203 (2011), 245–251.
8. Kelly-Cobbs, A.I., Harris, A.K., Elgebaly, M.M., Li, W., Sachidanandam, K., Portik-Dobos, V., et al. Endothelial endothelin B receptor-mediated prevention of cerebrovascular remodeling is attenuated in diabetes because of up-regulation of smooth muscle endothelin receptors. J Pharmacol Exp Ther 337 (2011), 9–15.
9. Li, W., Kelly-Cobbs, A.I., Mezzetti, E.M., Fagan, S.C., Ergul, A., Endothelin-1-mediated cerebrovascular remodeling is not associated with increased ischemic brain injury in diabetes. Can J Physiol Pharmacol 88 (2010), 788–795.
10. Li, W., Sachidanandam, K., Ergul, A., Comparison of selective versus dual endothelin receptor antagonism on cerebrovascular dysfunction in diabetes. Neurol Res 33 (2011), 185–191.
11. Palomares, S.M., Cipolla, M.J., Vascular protection following cerebral ischemia and reperfusion. J Neurol Neurophysiol, 2011 (Sep 20; pii: S1- 004).
12. Prakash, R., Somanath, P.R., El-Remessy, A.B.., Kelly-Cobbs, A., Stern, J.E., Dore-Duffy, P., et al. Enhanced cerebral but not peripheral angiogenesis in the Goto-Kakizaki model of type 2 diabetes involves VEGF and peroxynitrite signaling. Diabetes 61 (2012), 1533–1542.
13. Prakash, R., Johnson, M., Fagan, S.C., Ergul, A., Cerebral neovascularization and remodeling patterns in two different models of type 2 diabetes. PLoS One, 8, 2013, e56264.
14. Roger, V.L., Go, A.S., Lloyd-Jones, D.M., Benjamin, E.J., Berry, J.D., Borden, W.B., et al. Heart disease and stroke statistics — 2012 update: a report from the American Heart Association. Circulation 125 (2012), e2–e220.
15. Sachidanandam, K., Elgebaly, M.M., Harris, A.K., Hutchinson, J.R., Mezzetti, E.M., Portik-Dobos, V., et al. Effect of chronic and selective endothelin receptor antagonism on microvascular function in type 2 diabetes. Am J Physiol Heart Circ Physiol 294 (2008), H2743–H2749.
16. Sachidanandam, K., Hutchinson, J.R., Elgebaly, M.M., Mezzetti, E.M., Dorrance, A.M., Motamed, K., et al. Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1. Am J Physiol Regul Integr Comp Physiol 296 (2009), R952–R959.
17. Sachidanandam, K., Hutchinson, J.R., Elgebaly, M.M., Mezzetti, E.M., Wang, M.H., Ergul, A., Differential effects of diet-induced dyslipidemia and hyperglycemia on mesenteric resistance artery structure and function in type 2 diabetes. J Pharmacol Exp Ther 328 (2009), 123–130.
18. Sachidanandam, K., Portik-Dobos, V., Kelly-Cobbs, A.I., Ergul, A., Dual endothelin receptor antagonism prevents remodeling of resistance arteries in diabetes. Can J Physiol Pharmacol 88 (2010), 616–621.
19. Spinella, F., Rosano, L., Del Duca, M., Di Castro, V., Nicotra, M.R., Natali, P.G., et al. Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells. PLoS One, 5, 2010, e11241.
20. Standards of medical care in diabetes. Diabetes Care 34:Suppl. 1 (2011), S11–S61.